Summary
Dr. Ronald Hoffman discusses a caller's question about whether NAC could help with early Parkinson's disease. He explains how Dr. Perlmutter first proposed using intravenous glutathione for Parkinson's patients and how NAC serves as an oral precursor to glutathione that crosses the blood-brain barrier. Hoffman reviews a preclinical study showing NAC increases dopamine release and protects dopamine-producing neurons from neurodegeneration. The episode also covers lithium orotate research for Alzheimer's and the MAHA report on children's health trends.
Key Points
- NAC is a precursor to glutathione that can be taken orally and crosses the blood-brain barrier
- A preclinical study found NAC increases dopamine release and protects dopamine-producing neurons
- Dr. Perlmutter showed intravenous glutathione can rapidly improve tremors and balance in Parkinson's patients
- Recommended NAC dosage is 600mg two to three times daily
- The FDA attempted to ban NAC but public pushback kept it available over-the-counter
- Lithium orotate shows promise for Alzheimer's in a Nature study using mouse models
Key Moments
NAC as a precursor to glutathione for Parkinson's disease
Dr. Hoffman explains that NAC is a precursor to glutathione, allowing the body to produce its own glutathione orally rather than requiring expensive intravenous treatments. He notes NAC nearly got banned by the FDA but public pushback kept it available over-the-counter.
"And N-acetylcysteine, or NAC, by the way, something that was going to be banned by the FDA, but thanks to a big uproar on the part of you folks out there, we got the word out about the blooming ban, and there was a lot of pushback, and now N-acetylcysteine remains available over-the-counter."
Preclinical study shows NAC increases dopamine release and protects neurons
Dr. Hoffman reviews a preclinical study showing NAC increases dopamine release from neurons and protects dopamine-producing cells from the neurodegenerative processes that kill them in Parkinson's patients, validating NAC's potential to restore dopamine homeostasis.
"Cells in a test tube fed N-acetylcysteine have increased dopamine release and are protected from the neurodegenerative processes that kill off dopamine-producing cells in the brains of Parkinson's patients."
NAC crosses the blood-brain barrier making oral supplementation effective
Dr. Hoffman recommends 600mg of NAC two to three times daily and notes that NAC readily crosses the blood-brain barrier when taken orally, making it available to brain cells as both a glutathione precursor and a free radical scavenger.
"It's one of those compounds that actually you can take by mouth and it will cross into the brain and it will be made available to brain cells"
